JP2018514511A - 乳房障害とエストロゲン関連障害の処置のための組成物と方法 - Google Patents
乳房障害とエストロゲン関連障害の処置のための組成物と方法 Download PDFInfo
- Publication number
- JP2018514511A JP2018514511A JP2017550122A JP2017550122A JP2018514511A JP 2018514511 A JP2018514511 A JP 2018514511A JP 2017550122 A JP2017550122 A JP 2017550122A JP 2017550122 A JP2017550122 A JP 2017550122A JP 2018514511 A JP2018514511 A JP 2018514511A
- Authority
- JP
- Japan
- Prior art keywords
- breast
- fatty acid
- pharmaceutical composition
- vitamin
- omega
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147536P | 2015-04-14 | 2015-04-14 | |
| US62/147,536 | 2015-04-14 | ||
| PCT/US2016/026170 WO2016168021A1 (en) | 2015-04-14 | 2016-04-06 | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514511A true JP2018514511A (ja) | 2018-06-07 |
| JP2018514511A5 JP2018514511A5 (cg-RX-API-DMAC7.html) | 2019-04-11 |
Family
ID=57127000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550122A Pending JP2018514511A (ja) | 2015-04-14 | 2016-04-06 | 乳房障害とエストロゲン関連障害の処置のための組成物と方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180049999A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3283061A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018514511A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107708678A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016247674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2981301A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016168021A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111420046A (zh) * | 2020-05-27 | 2020-07-17 | 畜科生物工程有限公司 | 一种动物疫苗佐剂及其制备方法 |
| JP2022507265A (ja) * | 2018-11-14 | 2022-01-18 | ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Rad51阻害薬としての求電子剤および求電子剤プロドラッグ |
| JP2023518245A (ja) * | 2020-03-18 | 2023-04-28 | アール.ピー.シェーラー テクノロジーズ,エルエルシー | ソフトゲルカプセル |
| WO2023211005A1 (ko) * | 2022-04-25 | 2023-11-02 | 유엠에스엔지니어링 주식회사 | 오메가 3 심리스 연질캡슐 제조방법 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180169034A1 (en) * | 2015-06-14 | 2018-06-21 | Trs Ii, Llc | Transdermal delivery formulation |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
| CN110099680B (zh) | 2016-10-11 | 2021-02-05 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
| CN111212635A (zh) * | 2017-09-11 | 2020-05-29 | 阿托莎医疗公司 | 局部用组合物 |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES |
| TW201919594A (zh) * | 2017-09-11 | 2019-06-01 | 美商艾陶莎基因有限公司 | 局部用組合物及治療方法 |
| CA3094072A1 (en) * | 2018-03-15 | 2019-09-19 | Atossa Therapeutics, Inc. | In situ methods of inducing of immune response |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| WO2019232485A1 (en) * | 2018-05-31 | 2019-12-05 | Nvigen, Inc. | Accurate blood test to predict cancer incidence, recurrence, guide and monitor treatment intervention |
| IT201900003843A1 (it) * | 2019-03-15 | 2020-09-15 | Lo Li Pharma Srl | Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG) |
| EP3980006A2 (en) * | 2019-06-07 | 2022-04-13 | Diomics Corporation | Topical time release delivery using layered biopolymer |
| WO2021003433A1 (en) * | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| BR112022001165A2 (pt) * | 2019-07-23 | 2022-05-17 | Scherer Technologies Llc R P | Formulações de cápsula de casca macia e métodos de preparação e uso das mesmas |
| US11915811B2 (en) * | 2019-09-03 | 2024-02-27 | Kaival Labs, Inc. | System and method for determining an appropriate dose of a product |
| WO2021231904A1 (en) * | 2020-05-14 | 2021-11-18 | Diomics Corporation | Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy |
| WO2022187511A1 (en) * | 2021-03-03 | 2022-09-09 | Veramorph Llc | Dissociating polymer matrix compositions of fulvestrant and methods of their making and use |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2025174794A1 (en) * | 2024-02-12 | 2025-08-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20013336U1 (de) * | 2000-08-02 | 2001-02-15 | Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München | Mund- und Zahnpflegegel |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149851A (en) * | 1990-10-25 | 1992-09-22 | The United States Of America As Represented By The Secretary Of Commerce | Process for preparing triglycerides containing polyunsaturated fatty acid moieties |
| US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| DE19738643C2 (de) * | 1997-09-04 | 2001-10-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung |
| WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| NZ552316A (en) * | 2006-12-22 | 2009-10-30 | Fonterra Co Operative Group | Dairy product and process |
| WO2008113177A1 (en) * | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US20090068190A1 (en) * | 2007-08-29 | 2009-03-12 | Drugtech Corporation | Anti-proliferative combinations |
| WO2014093313A1 (en) * | 2012-12-10 | 2014-06-19 | Jingxuan Kang | Compositions and methods for integrated metabolic interventions |
| US8728546B1 (en) * | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| MX370055B (es) * | 2013-04-22 | 2019-11-29 | Smartfish As | Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer. |
| CN103734512A (zh) * | 2013-12-20 | 2014-04-23 | 晓健科技(大连)有限公司 | 一种宠物猫补钙营养膏 |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
-
2016
- 2016-04-06 EP EP16780471.5A patent/EP3283061A4/en not_active Withdrawn
- 2016-04-06 AU AU2016247674A patent/AU2016247674A1/en not_active Abandoned
- 2016-04-06 CN CN201680034873.1A patent/CN107708678A/zh active Pending
- 2016-04-06 WO PCT/US2016/026170 patent/WO2016168021A1/en not_active Ceased
- 2016-04-06 US US15/561,249 patent/US20180049999A1/en not_active Abandoned
- 2016-04-06 JP JP2017550122A patent/JP2018514511A/ja active Pending
- 2016-04-06 CA CA2981301A patent/CA2981301A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20013336U1 (de) * | 2000-08-02 | 2001-02-15 | Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München | Mund- und Zahnpflegegel |
Non-Patent Citations (3)
| Title |
|---|
| BIOCHEM. CELL BIOL., (1994), 72, [11-12], P.537-545, JPN6020001143, ISSN: 0004324229 * |
| CHAM. BIOL. INTERACT., (2010), 188, [1], P.102-110, JPN6020001142, ISSN: 0004324228 * |
| INT. J. PHARM., (2010), 387, [1-2], P.161-166, JPN6020001141, ISSN: 0004324227 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022507265A (ja) * | 2018-11-14 | 2022-01-18 | ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Rad51阻害薬としての求電子剤および求電子剤プロドラッグ |
| JP7656922B2 (ja) | 2018-11-14 | 2025-04-04 | ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Rad51阻害薬としての求電子剤および求電子剤プロドラッグ |
| JP2023518245A (ja) * | 2020-03-18 | 2023-04-28 | アール.ピー.シェーラー テクノロジーズ,エルエルシー | ソフトゲルカプセル |
| JP7785682B2 (ja) | 2020-03-18 | 2025-12-15 | アール.ピー.シェーラー テクノロジーズ,エルエルシー | ソフトゲルカプセル |
| CN111420046A (zh) * | 2020-05-27 | 2020-07-17 | 畜科生物工程有限公司 | 一种动物疫苗佐剂及其制备方法 |
| CN111420046B (zh) * | 2020-05-27 | 2021-01-12 | 四川省畜牧科学研究院 | 一种动物疫苗佐剂及其制备方法 |
| WO2023211005A1 (ko) * | 2022-04-25 | 2023-11-02 | 유엠에스엔지니어링 주식회사 | 오메가 3 심리스 연질캡슐 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2981301A1 (en) | 2016-10-20 |
| EP3283061A4 (en) | 2019-04-17 |
| EP3283061A1 (en) | 2018-02-21 |
| WO2016168021A1 (en) | 2016-10-20 |
| AU2016247674A1 (en) | 2017-10-19 |
| CN107708678A (zh) | 2018-02-16 |
| US20180049999A1 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107708678A (zh) | 治疗乳房病症以及雌激素相关病症的组合物和方法 | |
| RU2275198C2 (ru) | Дроспиренон для гормональной заместительной терапии | |
| JP2026035600A (ja) | 送達増強エピネフリン組成物 | |
| JP6247685B2 (ja) | 実質的に水不溶性の薬物の送達のための医薬組成物 | |
| JP6938462B2 (ja) | 治療用化合物の脳への一方向送達のためのインプラント組成物 | |
| CN115698013B (zh) | Menin抑制剂和cyp3a4抑制剂的组合及其使用方法 | |
| CN102413821A (zh) | 经皮吸收型制剂 | |
| CN111132670A (zh) | 具有增强的渗透的药物组合物 | |
| JP6768682B2 (ja) | メラノーマの処置に使用するためのアピリモド | |
| CN102065900B (zh) | 经皮吸收促进剂和使用其的经皮给药制剂 | |
| CN111465391A (zh) | 具有增强的递送的肾上腺素和前药的组合物 | |
| JP6623084B2 (ja) | S/o型貼付剤 | |
| JP2020533343A (ja) | 局所用組成物 | |
| KR20060127875A (ko) | 아로마타제 억제제 요법-관련된 골다공증의 치료 | |
| CN111148512A (zh) | 包含渗透增强剂的递送药物组合物 | |
| JP2020533342A (ja) | 局所用組成物及び処置方法 | |
| TW200901989A (en) | Anti-tumor activity of CCI-779 in papillary renal cell cancer | |
| CN116808226A (zh) | 一种药物组合物及其制备方法和应用、含其的埋植剂 | |
| TW201202232A (en) | Treatment of GIST with masitinib | |
| JP2005528432A (ja) | ノルエチンドロン徐放処方物およびそれに関連する方法 | |
| Novorý et al. | Tamoxifen in cancer therapy | |
| HRP20020666A2 (en) | Drospirenone for hormone replacement therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171002 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171121 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171010 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200120 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200817 |